Research & Development Laboratories near Colwell ON (16 Result(s))

KFI is a veterinary contract research organization (CRO) that specializes in in-vivo GLP/GCP studies in dogs, cats and horses. We have a reputation for satisfying our clients by providing high quality services in a timely manner with the utmost attention to the latest scientific research and regulatory standards.

CAL provides analytical services for the quality control programs of regulated products with professional expertise for raw materials, finished products, and packaging materials. Good Manufacturing Practices (GMP) help assure regulatory authorities that the data submitted are a true reflection of the results obtained during the study and can therefore be relied upon when making risk or safety assessments for regulated consumer products.

CardioGenics is dedicated to develop more sensitive diagnostic test products to the IVD market. CardioGenics has started several developmental processes aimed to achieve its objective 'to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies'.CardioGenics' operating philosophy is that 'better diagnosis enhances the healthcare professionals' ability to provide better patient management which saves lives and reduces healthcare costs'. Fulfilling unmet clinical testing needs is the driving force behind CardioGenics' innovations.

CardioGenics is dedicated to develop more sensitive diagnostic test products to the IVD market. CardioGenics has started several developmental processes aimed to achieve its objective 'to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies'. operating philosophy is that 'better diagnosis enhances the healthcare professionals' ability to provide better patient management which saves lives and reduces healthcare costs'. Fulfilling unmet clinical testing needs is the driving force behind CardioGenics' innovations.

Viventia is developing and advancing the next generation of human antibody-based therapeutics for use in oncology. Our approach combines the specificity of an antibody with the potency of a cytotoxic payload to provide targeted therapies for the safer and more efficacious treatment of cancer patients. Viventia has developed a potent payload, deBouganin, that when coupled to a targeting antibody can effectively kill cancer cells without harming normal cells. This differential targeting enhances the therapeutic potential of our drugs and provides prolonged clinical benefit. The versatile deBouganin payload has been chemically conjugated to full length antibodies as well as fused to numerous antibody fragments and has been found to be safe and efficacious in the clinic.